Investigators identified a set of inflammatory proteins that appears to coincide with current and future risk of end-stage renal disease in individuals with diabetes.
The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.
Proteomics firm Proteomics International said this week that it has received a A$1 million (US$ 1 million) grant from Commercialisation Australia – an initiative of the Australian government – to develop its protein biomarkers for diabetic nephropathy into a companion diagnostic.
NEW YORK (GenomeWeb News) – EMD Millipore and Proteomic International have signed a collaborative agreement to validate biomarkers related to diabetic nephropathy, the firms said today.
The company presented a panel of 13 biomarkers for the disease at last month's Human Proteome Organization annual meeting and is looking for partners and funding to develop it as a commercial diagnostic.
